search
Back to results

Patient Decision Aid for Antidepressant Use in Pregnancy

Primary Purpose

Depression, Pregnancy

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Standard Resource Sheet
Patient Decision Aid
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Depression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

INCLUSION CRITERIA: Women who meet all of the following criteria:

  • Are aged over 18
  • Are planning a pregnancy or are <30 weeks pregnant at enrolment
  • Have been offered to start or continue an antidepressant as treatment for depression by their clinician a
  • Have moderate-to-high decisional conflict (score of >25 on the Decisional Conflict Scale)

EXCLUSION CRITERIA: Women who meet any of the following criteria:

  • Have had alcohol or drug abuse or dependence in the previous 12 months
  • Have active suicidal ideation or psychosis
  • Are incapable of consenting to participation
  • Have any major obstetric complications or foetal cardiac anomaly in the current or in a past pregnancy,
  • Are visually impaired
  • Do not have sufficient English language proficiency to use the PDA.

Sites / Locations

  • South London and Maudsley NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Standard Resource Sheet

Electronic Patient Decision Aid

Arm Description

Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).

The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important. At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.

Outcomes

Primary Outcome Measures

Feasibility, measured by 'Recruitment Rate'

Secondary Outcome Measures

Depression, measured by the Edinburgh Postnatal Depression Scale
Anxiety, measured by the Spielburg State-Trait Anxiety Inventory
Decisional conflict, measured by the Decisional Conflict Scale
Knowledge about antidepressant treatment in pregnancy
Intervention acceptability to patients, measured by the PDA Acceptability Questionnaire
Intervention acceptability to clinicians, measured by the Provider Perspective Survey
Treatment Decision(s)
Feasibility, measure by 'Time between recruitment to first log-in to the study website'
Feasibility, measured by 'Study Website Usage'
Composite measure comprised of: (1) number of participants who complete the PDA, (2)length of time required to complete the PDA, (3) number of log ins, (4) number of times the PDA is completed per participant, (5) total number of webpages viewed).
Feasibility, measured by 'Number of participants who follow-up with their physician during the intended timeline'
Feasibility, measured by 'The rate of follow-up data collection'

Full Information

First Posted
June 22, 2015
Last Updated
October 20, 2021
Sponsor
King's College London
Collaborators
University of Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT02492009
Brief Title
Patient Decision Aid for Antidepressant Use in Pregnancy
Official Title
Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy: a Pilot RCT
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
June 2015 (Actual)
Primary Completion Date
March 2017 (Actual)
Study Completion Date
November 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London
Collaborators
University of Toronto

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The proposed study is a pilot randomized controlled trial (RCT) of an electronic patient decision aid (PDA) for antidepressant use in pregnancy. The overall aim of this pilot RCT is to establish the feasibility of future large international RCT of the PDA's effectiveness.
Detailed Description
Depression in pregnancy is common, affecting up to 10% of women and represents serious risk to mother and infant. Unfortunately, antidepressant medication, a first-line treatment for depression in pregnancy, also comes with risks, making this a complex decision. Clinical care appears to be insufficient for ensuring that women make decisions that are consistent with their own values and with which they feel satisfied. Patient decision support tools can address such barriers. Canadian colleagues have created a patient decision aid (PDA) that has the potential to improve the decision-making process for women regarding antidepressant use in pregnancy in conjunction with clinical care. This study is a pilot RCT of the above PDA in London, to be conducted in parallel with a pilot RCT in Toronto.The overall objective of this project is to inform the development of a larger, international RCT to assess the efficacy of this PDA for antidepressant use in pregnancy. To achieve this objective, the investigators will assess the feasibility of the trial protocol to evaluate the PDA and determine the preliminary effect size for a larger multisite efficacy study. The primary outcome for this pilot study is the feasibility of conducting a large randomized controlled trial to evaluate the efficacy of the PDA. This includes feasibility (how well the trial protocol can be implemented), acceptability (usability and tolerability of the intervention) and adherence (the degree to which the trial protocol is followed). It is hypothesized that the protocol will be feasible, that the PDA will have a high degree of acceptability, and that adherence to the protocol will be high.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Pregnancy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
51 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard Resource Sheet
Arm Type
Placebo Comparator
Arm Description
Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
Arm Title
Electronic Patient Decision Aid
Arm Type
Active Comparator
Arm Description
The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important. At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.
Intervention Type
Behavioral
Intervention Name(s)
Standard Resource Sheet
Intervention Description
Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
Intervention Type
Behavioral
Intervention Name(s)
Patient Decision Aid
Intervention Description
The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important. At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.
Primary Outcome Measure Information:
Title
Feasibility, measured by 'Recruitment Rate'
Time Frame
Up to one year from when the study starts enrolling participants
Secondary Outcome Measure Information:
Title
Depression, measured by the Edinburgh Postnatal Depression Scale
Time Frame
(a) Baseline (pre-randomization) and (b) 4 Weeks post-randomization and (c) 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy)
Title
Anxiety, measured by the Spielburg State-Trait Anxiety Inventory
Time Frame
(a) Baseline (pre-randomization) and (b) 4 Weeks post-randomization and (c) 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy)
Title
Decisional conflict, measured by the Decisional Conflict Scale
Time Frame
Baseline (pre-randomization) and 4 Weeks post-randomization
Title
Knowledge about antidepressant treatment in pregnancy
Time Frame
Baseline (pre-randomization) and 4 Weeks post-randomization
Title
Intervention acceptability to patients, measured by the PDA Acceptability Questionnaire
Time Frame
4 Weeks post-randomization]
Title
Intervention acceptability to clinicians, measured by the Provider Perspective Survey
Time Frame
After follow-up data is complete (12 weeks postpartum if last patient was recruited in pregnancy, or 6 months after baseline interview if last patient was recruited when planning a pregnancy)
Title
Treatment Decision(s)
Time Frame
(a) Baseline (pre-randomization) and (b) 4 Weeks post-randomization and (c) 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy)
Title
Feasibility, measure by 'Time between recruitment to first log-in to the study website'
Time Frame
4 weeks post-randomization
Title
Feasibility, measured by 'Study Website Usage'
Description
Composite measure comprised of: (1) number of participants who complete the PDA, (2)length of time required to complete the PDA, (3) number of log ins, (4) number of times the PDA is completed per participant, (5) total number of webpages viewed).
Time Frame
4 Weeks post-randomization
Title
Feasibility, measured by 'Number of participants who follow-up with their physician during the intended timeline'
Time Frame
4 weeks post-randomization
Title
Feasibility, measured by 'The rate of follow-up data collection'
Time Frame
(a) 4 Weeks post-randomization and (b) 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Women who meet all of the following criteria: Are aged over 18 Are planning a pregnancy or are <30 weeks pregnant at enrolment Have been offered to start or continue an antidepressant as treatment for depression by their clinician a Have moderate-to-high decisional conflict (score of >25 on the Decisional Conflict Scale) EXCLUSION CRITERIA: Women who meet any of the following criteria: Have had alcohol or drug abuse or dependence in the previous 12 months Have active suicidal ideation or psychosis Are incapable of consenting to participation Have any major obstetric complications or foetal cardiac anomaly in the current or in a past pregnancy, Are visually impaired Do not have sufficient English language proficiency to use the PDA.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Louise M Howard, PhD
Organizational Affiliation
Section of Women's Mental Health, King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
South London and Maudsley NHS Foundation Trust
City
London
ZIP/Postal Code
SE5 8AF
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
31822489
Citation
Khalifeh H, Molyneaux E, Brauer R, Vigod S, Howard LM. Patient decision aids for antidepressant use in pregnancy: a pilot randomised controlled trial in the UK. BJGP Open. 2019 Dec 10;3(4):bjgpopen19X101666. doi: 10.3399/bjgpopen19X101666. Online ahead of print.
Results Reference
result
Links:
URL
https://bjgpopen.org/content/3/4/bjgpopen19X101666
Description
Related Info

Learn more about this trial

Patient Decision Aid for Antidepressant Use in Pregnancy

We'll reach out to this number within 24 hrs